Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective—: Small-molecule hypoxia-inducible factor prolyl 4-hydroxylase (HIF-P4H) inhibitors are being explored in clinical studies for the treatment of anemia. HIF-P4H-2 (also known as PHD2 or EglN1) inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. We studied here whether HIF-P4H-2 inhibition could also protect against atherosclerosis. Approach and Results—: Atherosclerosis development was studied in low-density lipoprotein (LDL) receptor–deficient mice treated with an oral HIF-P4H inhibitor, FG-4497, and in HIF-P4H-2-hypomorphic/C699Y-LDL receptor–mutant mice, all mice being fed a high-fat diet. FG-4497 administration to LDL receptor–deficient mice reduced the area of atherosclerotic plaques by ≈50% when compared with vehicle-treated controls and also reduced their weight gain, insulin resistance, liver and white adipose tissue (WAT) weights, adipocyte size, number of inflammation-associated WAT macrophage aggregates and the high-fat diet–induced increases in serum cholesterol levels. The levels of atherosclerosis-protecting circulating autoantibodies against copper-oxidized LDL were increased. The decrease in atherosclerotic plaque areas correlated with the reductions in weight, serum cholesterol levels, and WAT macrophage aggregates and the autoantibody increase. FG-4497 treatment stabilized HIF-1α and HIF-2α and altered the expression of glucose and lipid metabolism and inflammation-associated genes in liver and WAT. The HIF-P4H-2-hypomorphic/C699Y-LDL receptor–mutant mice likewise had a ≈50% reduction in atherosclerotic plaque areas, reduced WAT macrophage aggregate numbers, and increased autoantibodies against oxidized LDL, but did not have reduced serum cholesterol levels. Conclusions—: HIF-P4H-2 inhibition may be a novel strategy for protecting against the development of atherosclerosis. The mechanisms involve beneficial modulation of the serum lipid profile and innate immune system and reduced inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Regulation of Oxygen Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (2009) · Physiology · doi:10.1152/physiol.00045.2008 · Cited by 926
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560 · cited 1×
“1–mediated induction of FoxP3 and increase in abundance and function of regulatory T cell (Tregs).(29) Because Tregs,”
BackgroundTakeda, K., Ho, V. C., Takeda, H., Duan, L.-J., Nagy, A., & Fong, G.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00425-06 · Cited by 401
Interdependent roles for hypoxia inducible factor and nuclear factor‐κB in hypoxic inflammation
Taylor, C. T. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.157669 · Cited by 354
Matsuura, H., Ichiki, T., Inoue, E., Nomura, M., Miyazaki, R., Hashimoto, T., Ikeda, J., Takayanagi, R., Fong, G.-H., & Sunagawa, K. (2013) · Circulation · doi:10.1161/circulationaha.113.001742 · Cited by 77 · cited 1×
“HIF-P4H-2 inhibition leads to improved lipid and glucose metabolism, reduced serum cholesterol levels, and protection from obesity and metabolic dysfunction.(9,21,22) We present evidence here that pharmacological and genetic HIF-P4H-2 inhibition also protects from atherosclerosis development.”
BackgroundLaitala, A., Aro, E., Walkinshaw, G., Mäki, J. M., Rossi, M., Heikkilä, M., Savolainen, E.-R., Arend, M., Kivirikko, K. I., Koivunen, P., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441824 · Cited by 58
Self-citation
Cited by
The effect of HIF on metabolism and immunity
Taylor, C. T., & Scholz, C. C. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00587-8 · Cited by 517
The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
Hypoxia and hypoxia-inducible factors in diabetes and its complications
Catrina, S.-B., & Zheng, X. (2021) · Diabetologia · doi:10.1007/s00125-021-05380-z · Cited by 400
Hypoxia-inducible factors and the regulation of lipid metabolism
Mylonis, I., Simos, G., & Paraskeva, E. (2019) · Cells · doi:10.3390/cells8030214 · Cited by 316
Metadata
- Authors
- Rahtu-Korpela, L., Määttä, J., Dimova, E. Y., Hörkkö, S., Gylling, H., Walkinshaw, G., Hakkola, J., Kivirikko, K. I., Myllyharju, J., Serpi, R., & Koivunen, P.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-04
- Volume
- 36
- Issue
- 4
- Pages
- 608-617
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2309322850
- Cited by
- 90
- References
- 8
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis. https://app.cochat.ai/papers/10.1161/atvbaha.115.307136
- The paper
- Rahtu-Korpela, L., Määttä, J., Dimova, E. Y., Hörkkö, S., Gylling, H., Walkinshaw, G., Hakkola, J., Kivirikko, K. I., Myllyharju, J., Serpi, R., & Koivunen, P. (2016). Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.115.307136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.